OncoMatch/Clinical Trials/NCT05553041
18F-Fluciclovine PET-MRI in High-grade Glioma
Is NCT05553041 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 18F-Fluciclovine PET-MRI for glioma.
Treatment: 18F-Fluciclovine PET-MRI — The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Lab requirements
Kidney function
history of abnormal kidney function or creatinine >= CTCAE v5.0 grade 2 at time of study registration [excluded]
Participants with a history of abnormal kidney function or creatinine >= CTCAE v5.0 grade 2 at time of study registration [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05553041 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages